Adir Et Compagnie

Emmanuel Canet

Michel Lonchampt

Guillaume De Nanteuil

Bernard Portevin

Jean-Luc Fauchere

Georges Remond

Jacqueline Bonnet

Alain Dhainaut

Yves Rolland

Graham Birrell

Nathalie Kucharczyk-Gentric

Tony Verbeuren

Gilbert Regnier

Michel Vincent

Christophe Thurieau

Michel Wierzbicki

Claude Guillonneau

Yolande Herve

Yves Charton

Marie-Odile Vallez

Joseph Paladino

Guy Lewin

Marie-Francedillaoise Boussard

Andre Tizot

New N-substituted cyclic amines of formula: ##STR1## wherein: X, R.sub.1, R.sub.2 and R are as defined in the description, their optical and geometric isomers and physiologically tolerable salts thereof. The compounds of the invention are powerful PDE4 inhibitors and can be used therapeutically.

N-substituted piperidines as PDE4 inhibitors

A compound of general formula (I): ##STR1## in which: R.sub.1 represents alkyl,

Flavone compounds

A compound of formula (I): ##STR1## in which: R.sub.1 represents an indolyl, naphthyl, tetrahydronaphthyl, thienyl, phenyl, optionally substituted, or (C.sub.3 -C.sub.7)cycloalkyl group,

Pseudopeptides derived from neurokinins

The invention provides new compounds pertaining to the class of: aryl methoxy phenyl alkyl heterocyclic spiro compounds, enantiomers, diastereoisomers and physiologically-tolerable salts thereof. For example: 8-{2-�3-quinol-2-yl methoxy)phenyl!ethyl}-3,8-diaza-1-oxa-2-oxo spiro�4,5!decane is described. Medicinal products containing the same are useful in the treatment of any pathology involving modifications of leukotriene metabolism.

Heterocyclic spiro compounds

The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl, phenyl, naphthyl, pyridyl or thienyl group, each phenyl, naphthyl, pyridyl or thienyl optionally being substituted,

Piperidine compounds

Disclosed herein are new diosmetin compounds of formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description. The said compounds are useful in the treatment of chronic venous insufficiency.

Diosmetin compounds

Compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl or (C.sub.3 -C.sub.7) cycloalkyl R.sub.2 represents alkyl, or (C.sub.3 -C.sub.7) cycloalkyl, R.sub.3 represents hydrogen or alkyl, R.sub.4 represents halogen or alkyl or alkoxy, R.sub.5 represents alkyl, X and Y, which are different, represent CO or SO.sub.2, n represents 1, 2 or 3, p represents 0 or 1, Z represents sulfur or oxygen, A represents any one of the following groups: ##STR2## in which: A.sub.1 represents, with the nitrogen and carbon atoms to which it is attached, a mono- or bicyclic heterocycle, .cndot. or, ##STR3## in which: R.sub.6 represents hydrogen, alkyl or cycloalkyl or 2-indanyl, R.sub.7 represents hydrogen or alkyl, which compounds of formula (I) comprise thereof corresponding hydrates of the ketone function COCF.sub.3, the enantiomers, diastereoisomers and epimers thereof and the addition salts thereof with a pharmaceutically acceptable base and medical products containing the same are useful as HLE inhibitor.

Peptides derived from trifluoromethylketones

Compounds of formula (I): ##STR1## wherein: R.sub.1 represents an unsubstituted or substituted alkyl,

A compound of formula (I): ##STR1## in which: R represents naphthyl, 5,6,7,8-tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, thienyl, optionally substituted phenyl or (C.sub.3 -C.sub.7)cycloalkyl,

Growing community of inventors

Paris, France

Emmanuel Canet